結核治療薬の世界市場レポート 2025年

結核治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.32％で25億7,000万米ドルに成長します。予測期間中に予想される成長の原動力は、ヘルスケアインフラへの投資の増加、啓発・教育活動の強化、研究開発への投資の拡大、各種抗結核薬の製品承認の増加、研究資金の拡大、高齢者人口の増加などです。この期間に予想される主な動向としては、薬剤開発の進歩、個別化医療の台頭、併用療法、デジタルヘルスソリューションの統合、創薬におけるAIや機械学習の活用などが挙げられます。

結核・HIV重複感染率の増加は、今後数年間の結核治療薬市場の成長を促進すると予想されます。結核・HIV同時感染とは、結核とヒト免疫不全ウイルス（HIV）に同時に感染している人を指します。共感染の増加は、高リスク集団におけるこれらの疫病の世界の重複とともに、結核への感受性を高めるHIVによる免疫系抑制に起因しています。結核治療薬は、HIVに関連する免疫抑制を緩和しながら結核と闘う標的治療を提供することにより、患者の転帰を改善し、二重の疾病負担を軽減することで、これらの重複感染症に対処する上で重要な役割を果たしています。例えば、2023年10月にgov.ukが発表したデータによると、イングランドでは2022年に3,805件の新規HIV診断が記録され、2021年に報告された3,118件から22％増加しました。このような共感染率の上昇が、結核治療薬の需要を大きく促進しています。

結核治療薬市場の主要企業は、治療効果を高め、治療期間を短縮し、薬剤耐性結核菌に対処するために、併用療法などの進歩に注力しています。併用療法は、治療効果を高め、耐性を最小限に抑え、患者の転帰全体を改善するために、異なるクラスの薬剤を2種類以上使用するものです。例えば、ジョンソン・エンド・ジョンソンは2024年7月、SIRTURO（ベダキリン）を米国FDAと欧州委員会から承認され、画期的な進歩を遂げました。SIRTUROは、多剤耐性結核（MDR-TB）用に特別に設計された40年以上ぶりの薬剤です。結核菌のエネルギー産生に重要なATP合成酵素を標的とすることで、SIRTUROは的を絞った強力な治療オプションを提供します。併用療法に組み込むことで、レジメンの有効性を高め、治療期間を短縮し、患者のアドヒアランス向上を促進します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界結核治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の結核治療薬市場：成長率分析
• 世界の結核治療薬市場の実績：規模と成長, 2019-2024
• 世界の結核治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界結核治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の結核治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 活動性結核（TB）
• 潜在性結核（TB）
• 世界の結核治療薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イソニアジド
• リファンピシン
• ピラジナミド
• ヒドラジン誘導体
• その他の抗結核薬
• エタンブトール
• 世界の結核治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の結核治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の結核治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界の結核治療薬市場活動性結核（TB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一選択薬（リファンピシン、イソニアジド、ピラジナミド、エタンブトール）
• 第二選択薬（フルオロキノロン、アミノグリコシド）
• 併用療法
• 薬剤耐性結核治療（MDR-TB、XDR-TB）
• 世界の結核治療薬市場潜在性結核（TB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イソニアジド予防
• リファンピシンベースのレジメン
• リファペンチンベースのレジメン
• 併用予防療法

第7章 地域別・国別分析

• 世界の結核治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の結核治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 結核治療薬市場：競合情勢
• 結核治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Novartis AG
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Macleods Pharmaceuticals Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Alkem Laboratories Limited
• Emcure Pharmaceuticals Limited
• Otsuka Pharmaceutical Co. Ltd.
• Sequella Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 結核治療薬市場2029：新たな機会を提供する国
• 結核治療薬市場2029：新たな機会を提供するセグメント
• 結核治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tuberculosis therapeutics encompass pharmaceutical treatments aimed at preventing and curing tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. These treatments focus on eradicating the bacteria, reducing transmission, and improving outcomes for patients, particularly those with drug-resistant strains.

The primary types of tuberculosis therapeutics are active tuberculosis (TB) and latent tuberculosis (TB). Active tuberculosis is a contagious bacterial infection that primarily affects the lungs, leading to symptoms such as persistent cough, fever, and weight loss. Available product types include isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. The treatments are administered via various routes, such as oral, parenteral, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The tuberculosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides tuberculosis therapeutics market statistics, including the tuberculosis therapeutics industry global market size, regional shares, competitors with the tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth during the historical period can be attributed to the increasing incidence of tuberculosis, the rising adoption of tuberculosis therapeutics, greater awareness of tuberculosis (TB), the growing prevalence of XDR-TB, and the increasing cases of drug-resistant tuberculosis.

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The anticipated growth in the forecast period is driven by increased investments in healthcare infrastructure, heightened awareness and education efforts, greater investment in research and development, an increase in product approvals for various anti-TB agents, expanded research funding, and a growing geriatric population. Key trends expected during this period include advancements in drug development, the rise of personalized medicine, combination therapies, integration of digital health solutions, and the use of AI and machine learning in drug discovery.

The increasing rates of TB-HIV co-infections are expected to drive the growth of the tuberculosis therapeutics market in the coming years. TB-HIV co-infection refers to individuals simultaneously infected with tuberculosis (TB) and human immunodeficiency virus (HIV). The rise in co-infections is attributed to the immune system suppression caused by HIV, which increases susceptibility to TB, along with the global overlap of these epidemics in high-risk populations. Tuberculosis therapeutics play a crucial role in addressing these co-infections by providing targeted treatments that combat TB while mitigating HIV-related immune suppression, thereby improving patient outcomes and alleviating the dual disease burden. For example, in October 2023, data from gov.uk indicated that England recorded 3,805 new HIV diagnoses in 2022, reflecting a 22% increase from the 3,118 cases reported in 2021. Such rising co-infection rates are significantly fueling the demand for tuberculosis therapeutics.

Leading companies in the tuberculosis therapeutics market are focusing on advancements such as combination therapies to enhance treatment effectiveness, shorten therapy durations, and address drug-resistant tuberculosis strains. Combination therapy utilizes two or more drugs from different classes to boost treatment efficacy, minimize resistance, and improve overall patient outcomes. For instance, in July 2024, Johnson & Johnson achieved a breakthrough with the approval of SIRTURO (bedaquiline) by the U.S. FDA and the European Commission. SIRTURO is the first drug in over 40 years specifically designed for multidrug-resistant tuberculosis (MDR-TB). By targeting the ATP synthase enzyme critical for TB bacteria's energy production, SIRTURO offers a targeted and potent treatment option. When incorporated into combination therapies, it enhances regimen efficacy, reduces treatment timelines, and promotes better patient adherence.

In May 2024, BioVersys AG, a Swiss biotechnology company, entered into a strategic partnership with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. This collaboration aims to advance innovative therapeutic solutions for TB. GSK plc, a UK-based pharmaceutical company, is known for its contributions to developing and manufacturing groundbreaking medicines, including treatments for tuberculosis.

Major players in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberculosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberculosis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberculosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tuberculosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberculosis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)
• 2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol
• 3) By Route of Administration: Oral; Parenteral; Other route of administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
• 2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tuberculosis Therapeutics Market Characteristics

3. Tuberculosis Therapeutics Market Trends And Strategies

4. Tuberculosis Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tuberculosis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tuberculosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tuberculosis Therapeutics Market Growth Rate Analysis
• 5.4. Global Tuberculosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tuberculosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tuberculosis Therapeutics Total Addressable Market (TAM)

6. Tuberculosis Therapeutics Market Segmentation

• 6.1. Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Active Tuberculosis (TB)
• Latent Tuberculosis (TB)
• 6.2. Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isoniazid
• Rifampin
• Pyrazinamide
• Hydrazine Derivatives
• Miscellaneous Anti-Tubercular Drugs
• Ethambutol
• 6.3. Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administration
• 6.4. Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.6. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
• Second-Line Drugs (Fluoroquinolones, Aminoglycosides)
• Combination Therapies
• Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
• 6.7. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isoniazid Prophylaxis
• Rifampicin-Based Regimens
• Rifapentine-Based Regimens
• Combination Prophylactic Therapies

7. Tuberculosis Therapeutics Market Regional And Country Analysis

• 7.1. Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tuberculosis Therapeutics Market

• 8.1. Asia-Pacific Tuberculosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tuberculosis Therapeutics Market

• 9.1. China Tuberculosis Therapeutics Market Overview
• 9.2. China Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tuberculosis Therapeutics Market

• 10.1. India Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tuberculosis Therapeutics Market

• 11.1. Japan Tuberculosis Therapeutics Market Overview
• 11.2. Japan Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tuberculosis Therapeutics Market

• 12.1. Australia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tuberculosis Therapeutics Market

• 13.1. Indonesia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tuberculosis Therapeutics Market

• 14.1. South Korea Tuberculosis Therapeutics Market Overview
• 14.2. South Korea Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tuberculosis Therapeutics Market

• 15.1. Western Europe Tuberculosis Therapeutics Market Overview
• 15.2. Western Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tuberculosis Therapeutics Market

• 16.1. UK Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tuberculosis Therapeutics Market

• 17.1. Germany Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tuberculosis Therapeutics Market

• 18.1. France Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tuberculosis Therapeutics Market

• 19.1. Italy Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tuberculosis Therapeutics Market

• 20.1. Spain Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tuberculosis Therapeutics Market

• 21.1. Eastern Europe Tuberculosis Therapeutics Market Overview
• 21.2. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tuberculosis Therapeutics Market

• 22.1. Russia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tuberculosis Therapeutics Market

• 23.1. North America Tuberculosis Therapeutics Market Overview
• 23.2. North America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tuberculosis Therapeutics Market

• 24.1. USA Tuberculosis Therapeutics Market Overview
• 24.2. USA Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tuberculosis Therapeutics Market

• 25.1. Canada Tuberculosis Therapeutics Market Overview
• 25.2. Canada Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tuberculosis Therapeutics Market

• 26.1. South America Tuberculosis Therapeutics Market Overview
• 26.2. South America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tuberculosis Therapeutics Market

• 27.1. Brazil Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tuberculosis Therapeutics Market

• 28.1. Middle East Tuberculosis Therapeutics Market Overview
• 28.2. Middle East Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tuberculosis Therapeutics Market

• 29.1. Africa Tuberculosis Therapeutics Market Overview
• 29.2. Africa Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tuberculosis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Tuberculosis Therapeutics Market Competitive Landscape
• 30.2. Tuberculosis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Tuberculosis Therapeutics Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Astellas Pharma Inc.
• 31.8. Macleods Pharmaceuticals Ltd.
• 31.9. Cipla Limited
• 31.10. Hikma Pharmaceuticals plc
• 31.11. Lupin Limited
• 31.12. Alkem Laboratories Limited
• 31.13. Emcure Pharmaceuticals Limited
• 31.14. Otsuka Pharmaceutical Co. Ltd.
• 31.15. Sequella Inc.

32. Global Tuberculosis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberculosis Therapeutics Market

34. Recent Developments In The Tuberculosis Therapeutics Market

35. Tuberculosis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Tuberculosis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tuberculosis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tuberculosis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer